Unlock stock picks and a broker-level newsfeed that powers Wall Street.

European Penny Stocks: 3 Picks With Market Caps Over €40M

In This Article:

Amid cautious optimism in Europe, the pan-European STOXX Europe 600 Index managed a modest gain, reflecting investor reactions to U.S. trade policy developments and geopolitical efforts in Eastern Europe. As investors navigate these complex market conditions, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential growth opportunities despite being somewhat of a niche investment area today. In this article, we explore three European penny stocks that stand out for their financial strength and growth potential.

Top 10 Penny Stocks In Europe

Name

Share Price

Market Cap

Financial Health Rating

Angler Gaming (NGM:ANGL)

SEK3.92

SEK293.94M

★★★★★★

Netgem (ENXTPA:ALNTG)

€0.958

€32.08M

★★★★★★

Transferator (NGM:TRAN A)

SEK2.50

SEK244.2M

★★★★★★

Hifab Group (OM:HIFA B)

SEK3.68

SEK223.89M

★★★★★★

High (ENXTPA:HCO)

€2.74

€53.82M

★★★★★★

Bredband2 i Skandinavien (OM:BRE2)

SEK2.08

SEK1.99B

★★★★☆☆

I.M.D. International Medical Devices (BIT:IMD)

€1.47

€25.46M

★★★★★☆

Nurminen Logistics Oyj (HLSE:NLG1V)

€1.195

€96.26M

★★★★★☆

Deceuninck (ENXTBR:DECB)

€2.345

€324.54M

★★★★★☆

IMS (WSE:IMS)

PLN3.79

PLN128.46M

★★★★☆☆

Click here to see the full list of 425 stocks from our European Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Nanoform Finland Oyj

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nanoform Finland Oyj provides nanotechnology and drug particle engineering services to the pharmaceutical and biotech industries in Europe and the United States, with a market cap of €105.37 million.

Operations: The company generates €2.43 million in revenue from its expert services in nanotechnology and drug particle engineering.

Market Cap: €105.37M

Nanoform Finland Oyj, with a market cap of €105.37 million, operates in the nanotechnology and drug particle engineering sector but remains unprofitable with losses increasing over recent years. Despite generating €2.43 million in revenue, it is not forecast to achieve profitability within the next three years. The company benefits from being debt-free and having a seasoned management team with an average tenure of 6.1 years, which may provide stability amid its volatile share price performance. Nanoform's short-term assets significantly cover its liabilities, offering some financial resilience as it continues to present at industry events like BioAsia 2025.